- Article metrics
- Last updated: Wed, 4 Feb 2026 21:29:14 Z
Exploring the next generation of antibody–drug conjugates
Access & Citations
-
- 78k
- Article Accesses
-
- 417
- Citations
Citation counts are provided by Dimensions and depend on their data availability. Counts will update daily, once available.
Online attention
- 113 tweeters
- 3 blogs
- 1 Facebook pages
- 11 news outlets
- 447 Mendeley
This article is in the 98th percentile (ranked 5,459th) of the 416,936 tracked articles of a similar age in all journals and the 93rd percentile (ranked 2nd) of the 32 tracked articles of a similar age in Nature Reviews Clinical Oncology
View more on Altmetric
Altmetric calculates a score based on the online attention an article receives. Each coloured thread in the circle represents a different type of online attention. The number in the centre is the Altmetric score. Social media and mainstream news media are the main sources that calculate the score. Reference managers such as Mendeley are also tracked but do not contribute to the score. Older articles often score higher because they have had more time to get noticed. To account for this, Altmetric has included the context data for other articles of a similar age.
Mentions in news and blogs
-
Cancer Drugs: Strategies For Patenting Antibody-Drug Conjugate Inventions
The National Law Review -
News story from Springer Medizin on Thursday 21 November 2024
Springer Medizin -
A new era of targeted therapy with antibody–drug conjugates
The Medical News -
Cancer Drugs: Strategies For Patenting Antibody-Drug Conjugate Inventions
Recent Contributors to The National Law Review -
A new era of targeted therapy with antibody–drug conjugates
news-medical.net
This list highlights individual mainstream news articles and blogs that cite the article. Not all news and blogs link to articles in a way that Altmetric can pick up, so they are not representative of all media. Altmetric are responsible for the curation of this list and provide updates hourly.